“…The number of participants varied between 14 and 320. The radiopharmaceutical 99m Tc-MAG3 was administered in six studies [11, 17-19, 24, 25], 99m Tc-DTPA in five studies [9,12,13,20,22], 123 I-OIH in four studies [15,16,21,23], 99m Tc-EC in one study [10] and one study did not mention which radiopharmaceutical had been administered [14]. Five studies had a retrospective study design [15,17,22,24,25] and 12 studies had a prospective study design [9-14, 16, 18-21, 23].…”